Company: DAWN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001193125-25-264649
Chunk: 115

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Item 3
Chunk 115
---
 or modification of any such potential future arrangements; •any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;•additions and departures of key personnel;•strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;•if a product candidate we develop receives marketing authorization, the timing and terms of such approval and market acceptance and demand for such product;•the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing authorization and intend to commercialize on our own or jointly with future collaborators;•regulatory developments affecting current or future product candidates or products, if any, or those of our competitors;

92

•the amount of expense or gain associated with the change in value of the success payments and contingent consideration;•changes in general market and economic conditions, such as due to rising interest rates, inflation, changes in domestic and foreign currency rates, significant political or trade regulatory developments or changes in trade policy, global regional conflicts and public health epidemics;•business development activities, such as additional program in-licensing, which could result in up-front payments or increased development expenses; and•cybersecurity incidents. If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. The market price of our common stock is likely to be highly volatile, which could result in substantial losses for purchasers of our common stock. The market price of our common stock is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price paid. The market price for our common stock may be influenced by many factors, including the other risks described in this “Risk Factors” section and the following: •the success of our commercialization efforts for our product, OJEMDA;•results of preclinical studies or clinical trials by us or those of our competitors or by existing or future collaborators or licensing partners; •the timing and enrollment